Market Closed -
London S.E.
11:35:02 2024-05-21 am EDT
|
5-day change
|
1st Jan Change
|
16.5
GBX
|
0.00%
|
|
+4.76%
|
-76.43%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Capitalization
1 |
27.01
|
18.86
|
40.97
|
62.87
|
39.22
|
15.73
|
15.73
|
-
|
Enterprise Value (EV)
1 |
14.95
|
11.36
|
31.23
|
58.22
|
34.32
|
60.31
|
13.48
|
15.73
|
P/E ratio
|
-5.21
x
|
-4.02
x
|
-5.71
x
|
-11.8
x
|
-5.75
x
|
-11.3
x
|
-2.7
x
|
-1.94
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
61.7
x
|
-
|
629
x
|
-
|
80.2
x
|
29.5
x
|
-
|
EV / Revenue
|
-
|
37.1
x
|
-
|
582
x
|
-
|
72.5
x
|
25.3
x
|
-
|
EV / EBITDA
|
-2.46
x
|
-
|
-4.78
x
|
-9.28
x
|
-4.78
x
|
-10.1
x
|
-2.26
x
|
-
|
EV / FCF
|
-3.15
x
|
-
|
-5.68
x
|
-11.4
x
|
-5.82
x
|
-11
x
|
-2.34
x
|
-
|
FCF Yield
|
-31.7%
|
-
|
-17.6%
|
-8.8%
|
-17.2%
|
-9.08%
|
-42.8%
|
-
|
Price to Book
|
-
|
-
|
3.29
x
|
8.37
x
|
5.14
x
|
7.25
x
|
5.47
x
|
-
|
Nbr of stocks (in thousands)
|
43,563
|
43,865
|
59,817
|
59,872
|
73,307
|
95,312
|
95,312
|
-
|
Reference price
2 |
0.6200
|
0.4300
|
0.6850
|
1.050
|
0.5350
|
0.1650
|
0.1650
|
0.1650
|
Announcement Date
|
4/9/19
|
4/29/20
|
4/14/21
|
4/12/22
|
4/13/23
|
4/25/24
|
-
|
-
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net sales
1 |
-
|
0.3059
|
-
|
0.1
|
-
|
0.8316
|
0.5333
|
-
|
EBITDA
1 |
-6.074
|
-
|
-6.536
|
-6.274
|
-7.178
|
-5.971
|
-5.951
|
-
|
EBIT
1 |
-6.084
|
-5.585
|
-6.553
|
-6.287
|
-7.776
|
-6.736
|
-6.289
|
-8
|
Operating Margin
|
-
|
-1,825.62%
|
-
|
-6,286.95%
|
-
|
-810.05%
|
-1,179.19%
|
-
|
Earnings before Tax (EBT)
1 |
-6.008
|
-5.521
|
-6.481
|
-6.271
|
-7.712
|
-6.446
|
-6.387
|
-
|
Net income
1 |
-5.167
|
-4.708
|
-5.411
|
-5.339
|
-6.504
|
-5.657
|
-5.618
|
-8
|
Net margin
|
-
|
-1,539.02%
|
-
|
-5,339.48%
|
-
|
-680.3%
|
-1,053.48%
|
-
|
EPS
2 |
-0.1190
|
-0.1070
|
-0.1200
|
-0.0890
|
-0.0930
|
-0.0620
|
-0.0610
|
-0.0850
|
Free Cash Flow
1 |
-4.739
|
-
|
-5.494
|
-5.121
|
-5.893
|
-5.475
|
-5.768
|
-
|
FCF margin
|
-
|
-
|
-
|
-5,120.69%
|
-
|
-658.44%
|
-1,081.56%
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
4/9/19
|
4/29/20
|
4/14/21
|
4/12/22
|
4/13/23
|
4/25/24
|
-
|
-
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
12.1
|
7.5
|
9.74
|
4.65
|
4.9
|
6.38
|
2.25
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-4.74
|
-
|
-5.49
|
-5.12
|
-5.89
|
-5.48
|
-5.77
|
-
|
ROE (net income / shareholders' equity)
|
-35.7%
|
-
|
-53.6%
|
-53.5%
|
-85.9%
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
-
|
-
|
0.2100
|
0.1300
|
0.1000
|
0.1000
|
0.0300
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
0.02
|
0.02
|
0
|
0.03
|
0
|
0.65
|
0
|
-
|
Capex / Sales
|
-
|
6.85%
|
-
|
30.26%
|
-
|
66.52%
|
0.19%
|
-
|
Announcement Date
|
4/9/19
|
4/29/20
|
4/14/21
|
4/12/22
|
4/13/23
|
4/25/24
|
-
|
-
|
Last Close Price
0.165
GBP Average target price
1.933
GBP Spread / Average Target +1,071.72% Consensus |
1st Jan change
|
Capi.
|
---|
| -76.43% | 19.98M | | +7.70% | 115B | | +12.79% | 107B | | -13.33% | 22.31B | | -3.99% | 21.6B | | -6.37% | 18.23B | | -39.93% | 17.62B | | +6.91% | 14.26B | | +32.75% | 12.37B | | -28.34% | 8.28B |
Bio Therapeutic Drugs
|